



ADC-Centric Pipeline in Precision Oncology

	Modality	Program	Target	Technology	Payload (DAR)	Indication	Preclinical	IND enabling	P1	P2	P3
 ADC	Monospecific	OBI-992	TROP2	Proprietary Cysteine conjugation	Exatecan (DAR4)	Solid Tumor					
		OBI-902	TROP2	GlycOBI®	Exatecan (DAR4)	Solid Tumor					
		OBI-904	Nectin-4	GlycOBI®	Exatecan (DAR8)	Solid Tumor					
	Bispecific	OBI-201	TROP2 x HER2	GlycOBI®	Undisclosed	Solid Tumor					
	Bispecific & Dual	Undisclosed	c-MET x HER3	GlycOBI DUO™	Undisclosed	Solid Tumor					
	Prodrug	OBI-3424 [§]	AKR1C3	N/A	N/A	Liver (HCC) [†] & T-ALL [‡]					

* GlycOBI® and GlycOBI DUO™ are patented glycan-based technologies and are registered trademarks of OBI Pharma Inc.

† Clinical study conducted by Asentawits (China)

‡ Clinical study conducted by NIH-SWOG (US)

§ OBI owns global rights excluding China, Hong Kong, Macau, Taiwan, Japan, Korea, Singapore, Malaysia, Thailand, Turkey, and India.

以ADC為核心的精準癌症治療研發產品線

藥物類型	產品	標靶	技術	攜帶藥物&藥物抗體比	適應症	臨床前研究	IND 準備	一期	二期	三期
單抗	OBI-992	TROP2	創新半胱氨酸 (Cysteine) 鍵結	Exatecan (DAR4)	實體腫瘤	 ↗ NCT06480240				
	OBI-902	TROP2	GlycOBI®	Exatecan (DAR4)	實體腫瘤	 ↗ NCT07124117				
	OBI-904	Nectin-4	GlycOBI®	Exatecan (DAR8)	實體腫瘤					
雙抗	OBI-201	TROP2 x HER2	GlycOBI®	未公開	實體腫瘤					
雙抗雙藥	Undisclosed	c-MET x HER3	GlycOBI DUO™	未公開	實體腫瘤					
前驅型藥物	OBI-3424 ^{\$}	AKR1C3	N/A	N/A	肝癌 (肝細胞) [†] & 急性淋巴性血癌 (T細胞) [‡]	 ↗ NCT04315324 ↗ CTR20201908				

* GlycOBI® 與 GlycOBI DUO™ 為浩鼎專有醣鍵結技術且為浩鼎的專利商標

† 臨床試驗由 Asentawits (China) 進行

‡ 臨床試驗由 NIH-SWOG (US) 進行

\$ 浩鼎擁有 OBI-3424 在全球的獨家權利 (不包括以下之地區: 中國、香港、澳門、台灣、日本、南韓、新加坡、馬來西亞、泰國、土耳其、印度)。